Colistin susceptibility testing: Evaluation of reliability for cystic fibrosis isolates of Pseudomonas aeruginosa and Stenotrophomonas maltophilia

Journal of Antimicrobial Chemotherapy

Volumn 65, Issue 7, 2010, Pages 1416-1423

  Moskowitz, Samuel M ^a   Garber, Elizabeth ^b   Chen, Yunhua ^b   Clock, Sarah A ^b   Tabibi, Setareh ^b   Miller, Amanda K ^a,c   Doctor, Michael ^b   Saiman, Lisa ^b  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b Och Spine at New York Presbyterian Hospitals   (United States)

^c AMGEN INC   (United States)

Author keywords

Antibiotic resistance; Disc diffusion; MICs; Peptide antibiotics; Polymyxins

Indexed keywords

COLISTIN; POLYMYXIN; ANTIINFECTIVE AGENT;

AGAR DILUTION; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATE; BROTH DILUTION; COMPARATIVE STUDY; CONTROLLED STUDY; CYSTIC FIBROSIS; DISK DIFFUSION; EPSILOMETER TEST; NONHUMAN; PILOT STUDY; PSEUDOMONAS AERUGINOSA; RELIABILITY; REPRODUCIBILITY; STENOTROPHOMONAS MALTOPHILIA; COMPLICATION; DRUG EFFECTS; EVALUATION STUDY; GRAM NEGATIVE INFECTION; HUMAN; ISOLATION AND PURIFICATION; LABORATORY DIAGNOSIS; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; PROCEDURES; SENSITIVITY AND SPECIFICITY;

ANTI-BACTERIAL AGENTS; COLISTIN; CYSTIC FIBROSIS; FALSE POSITIVE REACTIONS; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS; MICROBIAL SENSITIVITY TESTS; PSEUDOMONAS AERUGINOSA; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; STENOTROPHOMONAS MALTOPHILIA;

EID: 77954184392     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkq131     Document Type: Article

References (36)

1. Moskowitz SM, Chmiel JF, Sternen DL et al. Clinical practice and genetic counseling for cystic fibrosis and CFTR-related disorders. Genet Med 2008; 10: 851-68.
2. Moskowitz SM, Gibson RL, Effmann EL. Cystic fibrosis lung disease: genetic influences, microbial interactions, and radiological assessment. Pediatr Radiol 2005; 35: 739-57.
3. Moskowitz SM, Silva SJ, Mayer-Hamblett N et al. Shiftingpatternsof inhaled antibiotic use in cystic fibrosis. Pediatr Pulmonol 2008; 43:874-81.
4. Frederiksen B, Koch C, Hoiby N. Antibiotic treatment of initial colonization with Pseudomonas aeruginosa postpones chronic infection and prevents deterioration of pulmonary function in cystic fibrosis. Pediatr Pulmonol 1997; 23: 330-5.
5. Vaara M. Agents that increase the permeability of the outer membrane. Microbiol Rev 1992; 56: 395-411.
6. Newton BA. The absorption of polymyxin by cell-wall preparations from Pseudomonas aeruginosa. J Gen Microbiol 1954; 10: iii-iv.
7. Catchpole CR, Andrews JM, Brenwald N et al. A reassessment of the in-vitro activity of colistin sulphomethate sodium. J Antimicrob Chemother 1997; 39: 255-60.
8. Schulin T. Invitro activityof the aerosolized agents colistin and tobramycin and five intravenous agents against Pseudomonas aeruginosa isolated from cystic fibrosis patients in southwestern Germany. J Antimicrob Chemother 2002; 49:403-6.
9. Li J, Turnidge J, Milne R et al. In vitro pharmacodynamic properties of colistin and colistin methanesulfonate against Pseudomonas aeruginosa isolates from patients with cystic fibrosis. Antimicrob Agents Chemother 2001; 45: 781-5.
10. Denton M, Kerr K, Mooney L et al. Transmission of colistin-resistant Pseudomonas aeruginosa between patients attending a pediatric cystic fibrosis center. Pediatr Pulmonol 2002; 34: 257-61.
11. Johansen HK, Moskowitz SM, Ciofu O et al. Spread of colistin resistant non-mucoid Pseudomonas aeruginosa among chronically infected Danish cystic fibrosis patients. J Cyst Fibros 2008; 7: 391-7.
12. Pitt TL, Sparrow M, Warner M et al. Survey of resistance of Pseudomonas aeruginosa from UK patients with cystic fibrosis to six commonly prescribed antimicrobial agents. Thorax 2003; 58: 794-6.
13. Landman D, Bratu S, Alam M et al. Citywide emergence of Pseudomonas aeruginosa strains with reduced susceptibility to polymyxin B. J Antimicrob Chemother 2005; 55:954-7.
14. Gales AC, Reis AO, Jones RN. Contemporary assessment of antimicrobial susceptibility testing methods for polymyxin B and colistin: review of available interpretative criteria and quality control guidelines. J Clin Microbiol 2001; 39: 183-90.
15. Hogardt M, Schmoldt S, Gotzfried M et al. Pitfalls of polymyxin antimicrobial susceptibility testing of Pseudomonas aeruginosa isolated from cystic fibrosis patients. J Antimicrob Chemother 2004; 54: 1057-61.
16. Tan TY, Ng SY. Comparison of Etest, Vitek and agar dilution for susceptibility testing of colistin. Clin Microbiol Infect 2007; 13: 541-4.
17. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing: Eighteenth Informational Supplement M100-S18. CLSI, Wayne, PA, USA, 2008.
18. Saiman L, Mehar F, Niu WW et al. Antibiotic susceptibility of multiply resistant Pseudomonas aeruginosa isolated from patients with cystic fibrosis, including candidates for transplantation. Clin Infect Dis 1996; 23: 532-7.
19. LiPuma JJ, Dulaney BJ, McMenamin JD et al. Development of rRNA-based PCR assays for identification of Burkholderia cepacia complex isolates recovered from cystic fibrosis patients. J Clin Microbiol 1999; 37: 3167-70.
20. San Gabriel P, Zhou J, Tabibi S et al. Antimicrobial susceptibility and synergy studies of Stenotrophomonas maltophilia isolates from patients with cystic fibrosis. Antimicrob Agents Chemother 2004; 48: 168-71.
21. Clinical and Laboratory Standards Institute. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically- Seventh Edition: Approved Standard M7-A7. CLSI, Wayne, PA, USA, 2006.
22. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Disk Susceptibility Tests-Ninth Edition; Approved Standard M2-A9. CLSI, Wayne, PA, USA, 2006.
23. Nicodemo AC, Araujo MR, Ruiz AS et al. In vitro susceptibility of Stenotrophomonas maltophilia isolates: comparison of disc diffusion, Etest and agar dilution methods. J Antimicrob Chemother2004; 53:604-8.
24. Tan TY, Ng LS. Comparison of three standardized disc susceptibility testing methods for colistin. J Antimicrob Chemother 2006; 58: 864-7.
25. National Committee for Clinical Laboratory Standards. Development of In Vitro Susceptibility Testing Criteria and Quality Control Parameters- Second Edition: Approved Guideline M23-A2. NCCLS, Wayne, PA, USA, 2001.
26. Burns JL, Saiman L, Whittier S et al. Comparison of agar diffusion methodologies for antimicrobial susceptibility testing of Pseudomonas aeruginosa isolates from cystic fibrosis patients. J Clin Microbiol 2000; 38: 1818-22.
27. Saiman L, Burns JL, Whittier S et al. Evaluation of reference dilution test methods for antimicrobial susceptibility testing of Pseudomonas aeruginosa strains isolated from patients with cystic fibrosis. J Clin Microbiol 1999; 37: 2987-91.
28. Matsen JM, Koepcke MJ, Quie PG. Evaluation of the Bauer-Kirby-Sherris-Turck single-disc diffusion method of antibiotic susceptibility testing. Antimicrobial Agents Chemother 1969; 9: 445-53.
29. Barry AL, Effinger LJ. Evaluation of two standardized disk methods for testing antimicrobial susceptibility of Pseudomonas aeruginosa and of the Enterobacteriaceae. Antimicrob Agents Chemother 1974; 6:452-9.
30. Galani I, Kontopidou F, Souli M et al. Colistin susceptibility testing by Etest and disk diffusion methods. Int J Antimicrob Agents 2008; 31:434-9.
31. van der Heijden IM, Levin AS, De Pedri EH et al. Comparison of disc diffusion, Etest and broth microdilution for testing susceptibility of carbapenem-resistant P. aeruginosa to polymyxins. Ann Clin Microbiol Antimicrob 2007; 6:8.
32. Moskowitz SM, Ernst RK, Miller SI. PmrAB, a two-component regulatory system of Pseudomonas aeruginosa that modulates resistance to cationic antimicrobial peptides and addition of aminoarabinose to lipid A. J Bacteriol 2004; 186: 575-9.
33. McPhee JB, Lewenza S, Hancock RE. Cationic antimicrobial peptides activate a two-component regulatory system, PmrA-PmrB, that regulates resistance to polymyxin B and cationic antimicrobial peptides in Pseudomonas aeruginosa. Mol Microbiol 2003; 50: 205-17.
34. Pamp SJ, Gjermansen M, Johansen HK et al. Tolerance to the antimicrobial peptide colistin in Pseudomonas aeruginosa biofilms is linked to metabolically active cells, and depends on the pmr and mexAB-oprM genes. Mol Microbiol 2008; 68: 223-40.
35. Li J, Coulthard K, Milne R et al. Steady-state pharmacokinetics of intravenous colistin methanesulphonate in patients with cystic fibrosis. J Antimicrob Chemother 2003; 52: 987-92.
36. Ratjen F, Rietschel E, Kasel D et al. Pharmacokinetics of inhaled colistin in patients with cystic fibrosis. J Antimicrob Chemother 2006; 57: 306-11.